Saturday 17 October 2026
Export ICCC’s income statement to Excel — free account
ImmuCell Corporation
ICCC Healthcare Biotechnology
ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024. In the quarter to June 2026, revenue grew 11.5%, EPS grew 233.3%, free cash flow grew 54.9% and total debt fell 15.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.75
0.19
+1.80%
Follow ICCC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.62 | 0.00 | 0.00 | 118.79 |
P/S ratio |
2.04 | 2.01 | 1.91 | 2.97 | |
P/FCF ratio |
75.74 | 44.02 | 16.73 | 21.53 | |
P/Operating CF |
(47.81) | 115.05 | 16.03 | 30.18 | |
P/B ratio |
1.90 | 2.05 | 1.97 | 2.90 | |
Price to Tangible BV |
1.90 | 2.06 | 1.97 | 2.91 | |
EV/Sales |
2.24 | 2.20 | 1.98 | 2.95 | |
EV/EBITDA |
12.21 | 13.72 | 11.53 | 14.40 | |
EV/Operating CF |
31.23 | 24.56 | 13.22 | 15.37 | |
EV/FCF |
83.24 | 48.22 | 17.28 | 21.40 | |
Quick Ratio |
1.61 | 1.82 | 2.43 | 2.65 | |
Current Ratio |
4.21 | 4.26 | 4.82 | 4.75 | |
Net Debt/EBITDA |
7.69 | 8.12 | 0.76 | (0.23) | |
Debt/Assets |
20.75% | 21.39% | 19.73% | 17.81% | |
Debt/Equity |
0.32 | 0.34 | 0.30 | 0.26 | |
Asset Turnover |
0.62 | 0.63 | 0.67 | 0.66 | |
Operating CF/Net income |
8.46 | (0.17) | 1.84 | 1.65 | |
Capex/Depreciation |
(0.84) | (0.24) | (0.31) | (1.55) | |
Research and Development Expense of Revenue |
12.61% | 9.95% | 3.07% | 1.67% | |
Selling, General and Administrative Expense of Revenue |
29.94% | 28.97% | 22.89% | 33.16% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.33% | 1.36% | 1.33% | 3.34% | |
Graham Net Nets |
0.02 | 0.03 | 0.07 | 0.06 | |
Graham Number |
4.43 | 0.00 | 0.00 | 2.57 | |
Earnings Yield |
4.23% | (1.71%) | (0.88%) | 0.84% | |
Free Cash Flow Yield |
1.32% | 2.27% | 5.98% | 4.64% | |
Revenue per Share |
0.61 | 0.84 | 1.15 | 0.79 | |
Operating CF per Share |
(0.13) | 0.05 | 0.40 | 0.33 | |
Capex per Share |
(0.07) | (0.02) | (0.02) | (0.08) | |
Free Cash Flow per Share |
(0.20) | 0.03 | 0.38 | 0.25 | |
Cash per Share |
0.43 | 0.42 | 0.75 | 0.98 | |
Shareholders Equity per Share |
3.29 | 3.00 | 3.22 | 3.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.29 | 3.00 | 3.22 | 3.46 | |
Free Cash Flow |
(1.77) | 0.32 | 3.41 | 2.29 | |
Working Capital |
12.83 | 12.97 | 14.95 | 16.64 | |
Capital Expenditures |
(0.59) | (0.17) | (0.17) | (0.73) | |
Net Current Asset Value |
0.90 | 1.47 | 3.89 | 5.82 | |
EV/EBIT |
26.69 | 36.87 | 23.65 | 23.42 | |
Capex to Sales |
0.11 | 0.02 | 0.02 | 0.10 | |
Price to Operating Income |
24.28 | 33.66 | 22.90 | 23.56 | |
| Other line items | |||||
Average Receivables |
2.43 | 3.60 | 3.02 | 2.64 | |
Average Payables |
2.41 | 2.38 | 2.08 | 2.70 | |
Average Inventory |
8.63 | 8.19 | 8.02 | 8.69 | |
Average Assets |
45.09 | 43.82 | 44.87 | 46.68 | |
Average Common Equity |
28.11 | 27.29 | 29.06 | 30.62 |
Columns are period end dates